Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?

Area of Science:

• Nuclear medicine
• Radiopharmaceutical therapy
• Oncology

Background:

• Beta-emitting radionuclides are limited in killing disseminated tumor cells due to electron energy deposition outside target cells.
• Alpha-particle emitting radionuclides present a potential solution due to their short range and high linear energy transfer.
• Optimizing alpha-immunotherapy requires careful selection of radionuclides, targeting molecules, and clinical applications.

Purpose of the Study:

• To evaluate the potential of alpha-particle emitting radionuclides for cancer therapy.
• To review clinically tested alpha-emitting radionuclides and their associated challenges.
• To define optimal conditions and indications for alpha-immunotherapy.

Main Methods:

• Review of four alpha-particle emitting radionuclides (213Bi, 225Ac, 212Pb, 211At) used in Phase I clinical studies.
• Assessment of radionuclide properties, carrier molecule compatibility, and half-life matching.
• Analysis of clinical safety and efficacy data for selected radionuclides.

Main Results:

• Clinical safety has been established for several alpha-emitters, with encouraging efficacy for 213Bi and 211At.
• 211At shows significant promise, while 225Ac and 212Pb are also of considerable interest.
• Carrier molecules labeled with beta-emitters can be adapted for alpha-emitters, provided half-life considerations are met.

Conclusions:

• Alpha-immunotherapy is most suitable for minimal residual disease, including isolated tumor cells or small malignant cell clusters, due to the short range of alpha particles.
• The selection of the appropriate alpha-emitting radionuclide and targeting strategy is critical for therapeutic success.
• Further research and clinical validation are essential to fully realize the potential of alpha-particle therapy.